Background: The Rise and Regulation of Compounded GLP-1 Drugs To appreciate the significance of the FDAs latest action, some context is necessary
Methods Study design The SEMPA trial (Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in Patients with Type 2 Diabetes A Randomized Trial) was a 32 week investigator-initiated, randomised, partly placebo-controlled, partly open-label trial, designed to assess the separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and arterial stiffness as two co-primary outcomes
This combo may help the body release more growth hormone
So I believe other factors are at play besides losing weight. David Greenberg, MD, FACP MNT spoke with Lauren Carcas, MD, a medical oncologist with Miami Cancer Institute, part of Baptist Health South Florida, about this studys findings, who commented that while theyre exciting, the data must be interpreted in context